Caribou’s first CRISPR CAR-T impresses

Caribou’s first CRISPR CAR-T impresses

Caribou expects these PD-1 knockout allogeneic CAR T therapies may overcome durability concerns to deliver therapies that are as effective as autologous anti-CD19 CAR T therapies but at a fraction of the cost. Caribou was co-founded in 2011 by, among others, CRISPR pioneer and Nobel laureate Jennifer Doudna.

This is a preview of subscription content

Access options

Subscribe to Journal

Get full journal access for 1 year

99,00 €

only 8,25 € per issue

Tax calculation will be finalised during checkout.

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

About this article

Cite this article

Caribou’s first CRISPR CAR-T impresses.
Nat Biotechnol 40, 807 (2022). https://doi.org/10.1038/s41587-022-01371-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-022-01371-6

Read More

Author: admin